查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1722140

第一代肝細胞市場 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2025年～2032年按)- 各產品，類別，用途/化驗，各終端用戶，各地區，各企業)

Primary Hepatocytes Market - Global Primary Hepatocytes Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product, By Species, By Application/Assay, By End User, By Geographic Coverage and By Company)
出版日期: | 出版商: Fairfield Market Research | 英文 180 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

預計未來幾年全球原代肝細胞市場規模將大幅成長，到2032年將達到4.069億美元。這比2025年的2.636億美元大幅成長，反映出2025年至2032年預測期間的複合年增長率（CAGR）為6.4%。這種快速增長主要得益於肝臟相關疾病盛行率的上升，以及藥物開發和毒性測試中對更具預測性的體外模型日益增長的需求。

市場洞察

原代肝細胞已成為肝病研究、臨床前藥物檢查和毒理學評估的基石。它們能夠精確模擬肝功能，使其成為研究藥物代謝、酵素活性和肝毒性的理想選擇。 3D培養系統的最新進展，例如球狀體和共培養技術，使得更忠實地模擬體內肝臟微環境成為可能，從而增強了基於肝細胞的檢測方法的實用性。

越來越多的研究人員和製藥公司開始使用幹細胞衍生的肝細胞，以克服供應限制，同時保持其功能完整性。這種趨勢，加上人們對倫理研究實踐日益增長的興趣以及減少動物試驗的監管壓力，正在推動基於肝細胞的體外系統廣泛應用。

市場推動因素

市場推動因素之一是肝病發生率的上升，包括非酒精性脂肪性肝病 (NAFLD) 和肝炎。這些疾病催生了對可靠體外模型的需求，這些模型能夠有效地支持藥物研發和治療測試。原代肝細胞與人類肝細胞較接近，是這方面的重要工具。

推動市場成長的另一個主要因素是全球癌症發生率的上升。世界衛生組織 (WHO) 預測，到 2040 年，癌症患者將增加 47%，這凸顯了對更有效的藥物篩選方法的迫切需求。 3D 肝細胞模型在評估藥物毒性和療效方面具有更高的預測能力，使其在腫瘤學研究中具有不可估量的價值。龍沙 (Lonza) 和賽默飛世爾科技 (Thermo Fisher Scientific) 等領先公司正在積極投資器官晶片和 3D 肝細胞模型，以滿足這一需求。

此外，FDA 和 EMA 等監管機構正在強調使用與人類相關的體外模型來改善早期藥物篩選並減少動物試驗。此類監管支持進一步鞏固了原代肝細胞在現代藥物研發中的作用。

商機

這個市場充滿了商機，尤其是人們對3D細胞培養技術的興趣日益濃厚。這些系統能夠重現複雜的組織結構，並能更準確地洞察腫瘤生長、轉移和抗藥性等生物過程。由患者來源的細胞建構的類器官正在為個人化醫療應用鋪平道路。

此外，更嚴格的動物實驗法規為基於肝細胞的模型開闢了新的途徑。企業正在利用這一轉變，開發符合不斷發展的倫理標準的創新篩選工具，同時提高臨床前研究的可靠性。對可擴展且經濟高效的解決方案的需求，為新創公司和新興企業創造了創新和拓展業務的機會。

區域分析

北美仍是全球原代肝細胞市場的主導地區。先進的醫療基礎設施、大量的研發投入以及強大的製藥和生物技術公司佔據關鍵地位。高發病率的肝病和支持創新藥物開發的監管環境也推動了需求的成長。

歐洲也是成長強勁的領先地區之一，這得益於成熟的製藥業和先進的監管政策。德國、法國和英國等國正率先將體外系統納入其藥物開發流程。歐洲藥品管理局 (EMA) 持續推廣動物試驗的替代方案，鼓勵更廣泛地採用原代肝細胞。

主要參與者

競爭格局的特徵是策略投資、產品創新以及產業領袖之間的聯盟。各公司正致力於改善細胞分離、冷凍保存和檢測適用性，以滿足不斷變化的市場需求。

近期產業趨勢

2024年3月，默克公司在上海投資1,400萬美元，成立了M Lab™合作中心，以擴展其新的生物應用和培訓實驗室，從而支持生物製藥研究。

2024年2月，默克公司在巴西聖保羅投資2,000萬美元開設了一個物流中心，以提高服務拉丁美洲生命科學客戶的效率。

2023年2月，ATCC與美國藥典(USP)建立長期合作夥伴關係，共同開發生物製劑參考物質和標準，以提高品質和合規性。

市場區隔

各產品

  • 凍存懸浮肝細胞
  • 新鮮懸浮肝細胞
  • 3D（球狀）肝細胞
  • 擴增肝細胞（可接種）
  • 去特化肝細胞

類別

  • 人
  • 大鼠
  • 小鼠
  • 狗
  • 猴子
  • 馬
  • 其他

各用途/化驗

  • 細胞活力測定
  • 細胞色素酶活性測定
  • 高含量細胞毒性測定
  • 轉運蛋白抑制測定
  • 在體外內源性清除
  • 磷脂測定
  • 其他

各終端用戶

  • 生物製藥公司
  • 學術研究機關
  • 受託研究機構

各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

本報告提供全球第一代肝細胞市場相關調查，市場概要，以及各產品，類別，用途/化驗，各終端用戶，向各地區趨勢，及市場參與市場企業的競爭趨勢等資訊。

目錄

第1章 摘要整理

第2章 市場概要

  • 市場定義和市場區隔
  • 市場動態
  • 價值鏈分析
  • 波特的五力分析
  • COVID-19影響分析
  • 經濟概要
  • 大環境分析
  • 第一代肝細胞市場，產品的招聘
  • 各地區的法規情勢
  • 價值鏈分析

第3章 全球第一代肝細胞市場預測，2019年～2032年

  • 全球第一代肝細胞市場預測:各產品，金額(100萬美元)，2019年～2032年
  • 全球第一代肝細胞市場預測:類別，金額(100萬美元)，2019年～2032年
  • 全球第一代肝細胞市場預測:各用途/化驗，金額(100萬美元)，2019-2032年
  • 全球第一代肝細胞市場預測:各終端用戶，金額(100萬美元)，2019年～2032年
  • 全球第一代肝細胞市場預測:各地區，金額(100萬美元)，2019年～2032年

第4章 北美的第一代肝細胞市場預測，2019年～2032年

第5章 歐洲的第一代肝細胞市場預測，2019年～2032年

第6章 亞太地區的第一代肝細胞市場預測，2019年～2032年

第7章 南美的第一代肝細胞市場預測，2019年～2032年

第8章 中東·非洲的第一代肝細胞市場預測，2019年～2032年

第9章 競爭情形

  • 2025年的企業市場佔有率分析
  • 競爭儀表板
  • 企業簡介
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Lonza
    • Takara Bio Inc.
    • American Type Culture Collection (ATCC)
    • Corning Inc.
    • Cell Biologics, Inc.
    • Creative Bioarray
    • Axol Bioscience Ltd.
    • HiMedia Laboratories
    • NEXEL Co., Ltd.
    • AnaBios
    • Cytes Biotechnologies S.L.
    • ZenBio, Inc. (BioIVT)
    • iXCells Biotechnologies
    • ScienCell Research Laboratories, Inc.
    • Kerafast
    • Kosheeka
    • XenoTech
    • LifeNet Health LifeSciences
    • Cell Guidance Systems LLC
    • Applied Biological Materials Inc. (abm)
    • Discovery Life Sciences
    • Innoprot
    • Novabiosis

第10章 附錄

簡介目錄

The global primary hepatocytes market is poised for substantial growth over the coming years, reaching an estimated valuation of US$ 406.9 million by 2032. This marks a significant increase from the US$ 263.6 million recorded in 2025, reflecting a compound annual growth rate (CAGR) of 6.4% during the forecast period from 2025 to 2032. The surge is largely attributed to the escalating prevalence of liver-related diseases and the increasing demand for more predictive in vitro models in drug development and toxicology testing.

Market Insights

Primary hepatocytes have become a cornerstone in liver disease research, preclinical drug testing, and toxicological assessments. Their ability to accurately mimic liver function makes them ideal for investigating drug metabolism, enzyme activity, and hepatotoxicity. Recent advancements in 3D culture systems, such as spheroids and co-culture technologies, are elevating the relevance of hepatocyte-based assays by enabling closer simulation of the in vivo liver microenvironment.

Researchers and pharmaceutical companies are increasingly turning to stem cell-derived hepatocytes to overcome supply limitations while maintaining functional integrity. This trend, coupled with a growing focus on ethical research practices and regulatory pressure to reduce animal testing, is driving the widespread adoption of hepatocyte-based in vitro systems.

Market Drivers

One of the key drivers of the market is the increasing incidence of liver diseases, including Non-Alcoholic Fatty Liver Disease (NAFLD) and hepatitis. These conditions are generating demand for reliable in vitro models that can effectively support drug discovery and therapeutic testing. Primary hepatocytes, which offer a close representation of human liver cells, are essential tools in this regard.

Another major factor fueling market growth is the global rise in cancer prevalence. The World Health Organization (WHO) anticipates a 47% increase in cancer cases by 2040, which underscores the urgent need for more effective drug screening methods. 3D hepatocyte models are proving invaluable in oncology research, offering greater predictive power in assessing drug toxicity and efficacy. Leading companies such as Lonza and Thermo Fisher Scientific are actively investing in organ-on-a-chip and 3D liver models to meet this demand.

Additionally, regulatory bodies like the FDA and EMA are emphasizing the use of human-relevant in vitro models to improve early-stage drug screening and reduce animal testing. This regulatory support is further solidifying the role of primary hepatocytes in modern drug development.

Business Opportunities

The market is brimming with opportunities, especially in the wake of growing interest in 3D cell culture technologies. These systems replicate complex tissue architecture, offering more accurate insights into biological processes such as tumor growth, metastasis, and drug resistance. Organoids created from patient-derived cells are paving the way for personalized medicine applications.

Moreover, stricter animal testing regulations are opening new avenues for hepatocyte-based models. Companies are capitalizing on this shift by developing innovative screening tools that align with evolving ethical standards while enhancing the reliability of preclinical studies. The demand for scalable, cost-effective solutions also presents opportunities for startups and emerging players to innovate and expand.

Regional Analysis

North America remains the dominant region in the global primary hepatocytes market. Its advanced healthcare infrastructure, substantial investment in R&D, and strong presence of pharmaceutical and biotechnology companies contribute to its leading position. The high incidence of liver disorders and a regulatory environment that supports innovative drug development practices are also driving demand.

Europe is another key region experiencing robust growth, fueled by its well-established pharmaceutical sector and progressive regulatory policies. Countries like Germany, France, and the United Kingdom are leading efforts in integrating in vitro systems into drug development pipelines. The European Medicines Agency (EMA) continues to promote alternatives to animal testing, thereby supporting increased adoption of primary hepatocytes.

Key Players

The competitive landscape is characterized by strategic investments, product innovations, and collaborations among major industry players. Companies are focusing on improving cell isolation techniques, cryopreservation technologies, and assay compatibility to meet the evolving demands of the market.

Prominent players in the primary hepatocytes market include:

  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza
  • Takara Bio Inc.
  • American Type Culture Collection (ATCC)
  • Corning Inc.
  • Cell Biologics, Inc.
  • Creative Bioarray
  • Axol Bioscience Ltd.
  • HiMedia Laboratories
  • AnaBios
  • Cytes Biotechnologies S.L.
  • ZenBio, Inc. (BioIVT)
  • iXCells Biotechnologies
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Kosheeka
  • XenoTech
  • LifeNet Health LifeSciences
  • Applied Biological Materials Inc. (abm)
  • Discovery Life Sciences
  • Innoprot
  • Novabiosis

Recent Industry Developments

In March 2024, Merck invested US$ 14 million in its M Lab(TM) Collaboration Center in Shanghai, expanding its offerings with new biological application and training labs to support biopharma research.

In February 2024, Merck opened a US$ 20 million distribution center in Sao Paulo, Brazil, aimed at improving service efficiency for its life science clients in Latin America.

In February 2023, ATCC entered a long-term partnership with the U.S. Pharmacopeia (USP) to co-develop reference materials and standards for biologic medicines, bolstering quality and compliance.

Market Segmentation

By Product:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

By Species:

  • Human
  • Rat
  • Mouse
  • Dog
  • Monkey
  • Horse
  • Others

By Application/Assay:

  • Cell Viability Assay
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assay
  • In Vitro Intrinsic Clearance
  • Phospholipids Assay
  • Others

By End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Economic Overview
    • 2.6.1. World Economic Projections
  • 2.7. PESTLE Analysis
  • 2.8. Primary Hepatocytes Market, Product Adoption
  • 2.9. Regulatory Scenario by Region
  • 2.10. Value Chain Analysis

3. Global Primary Hepatocytes Market Outlook, 2019-2032

  • 3.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cryopreserved Suspension Hepatocytes
      • 3.1.1.2. Fresh Suspension Hepatocytes
      • 3.1.1.3. 3D (Spheroid) Hepatocytes
      • 3.1.1.4. Expanded Hepatocytes (Plateable)
      • 3.1.1.5. Non-characterized Hepatocytes
  • 3.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Human
      • 3.2.1.2. Rat
      • 3.2.1.3. Mouse
      • 3.2.1.4. Dog
      • 3.2.1.5. Monkey
      • 3.2.1.6. Horse
      • 3.2.1.7. Others
  • 3.3. Global Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. Cell Viability Assay
      • 3.3.1.2. Cytochrome Enzyme Activity
      • 3.3.1.3. High Content Cytotoxicity
      • 3.3.1.4. Transporter Inhibition Assay
      • 3.3.1.5. In Vitro Intrinsic Clearance
      • 3.3.1.6. Phospholipids Assay
      • 3.3.1.7. Others
  • 3.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 3.4.1. Key Highlights
      • 3.4.1.1. Biopharmaceutical companies
      • 3.4.1.2. Academic and Research institutes
      • 3.4.1.3. Contract Research Organizations
  • 3.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn), 2019-2032
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. East Asia
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Primary Hepatocytes Market Outlook, 2019-2032

  • 4.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Cryopreserved Suspension Hepatocytes
      • 4.1.1.2. Fresh Suspension Hepatocytes
      • 4.1.1.3. 3D (Spheroid) Hepatocytes
      • 4.1.1.4. Expanded Hepatocytes (Plateable)
      • 4.1.1.5. Non-characterized Hepatocytes
  • 4.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Human
      • 4.2.1.2. Rat
      • 4.2.1.3. Mouse
      • 4.2.1.4. Dog
      • 4.2.1.5. Monkey
      • 4.2.1.6. Horse
      • 4.2.1.7. Others
  • 4.3. North America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Cell Viability Assay
      • 4.3.1.2. Cytochrome Enzyme Activity
      • 4.3.1.3. High Content Cytotoxicity
      • 4.3.1.4. Transporter Inhibition Assay
      • 4.3.1.5. In Vitro Intrinsic Clearance
      • 4.3.1.6. Phospholipids Assay
      • 4.3.1.7. Others
  • 4.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. Biopharmaceutical companies
      • 4.4.1.2. Academic and Research institutes
      • 4.4.1.3. Contract Research Organizations
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.3. U.S. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 4.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.7. Canada Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Primary Hepatocytes Market Outlook, 2019-2032

  • 5.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cryopreserved Suspension Hepatocytes
      • 5.1.1.2. Fresh Suspension Hepatocytes
      • 5.1.1.3. 3D (Spheroid) Hepatocytes
      • 5.1.1.4. Expanded Hepatocytes (Plateable)
      • 5.1.1.5. Non-characterized Hepatocytes
  • 5.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Human
      • 5.2.1.2. Rat
      • 5.2.1.3. Mouse
      • 5.2.1.4. Dog
      • 5.2.1.5. Monkey
      • 5.2.1.6. Horse
      • 5.2.1.7. Others
  • 5.3. Europe Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cell Viability Assay
      • 5.3.1.2. Cytochrome Enzyme Activity
      • 5.3.1.3. High Content Cytotoxicity
      • 5.3.1.4. Transporter Inhibition Assay
      • 5.3.1.5. In Vitro Intrinsic Clearance
      • 5.3.1.6. Phospholipids Assay
      • 5.3.1.7. Others
  • 5.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Biopharmaceutical companies
      • 5.4.1.2. Academic and Research institutes
      • 5.4.1.3. Contract Research Organizations
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.3. Germany Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.7. U.K. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.11. France Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.13. Spain Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.14. Spain Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.15. Spain Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.16. Spain Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.17. Italy Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.18. Italy Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.19. Italy Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.20. Italy Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.23. Russia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.27. Rest of Europe Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia & Pacific Primary Hepatocytes Market Outlook, 2019-2032

  • 6.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cryopreserved Suspension Hepatocytes
      • 6.1.1.2. Fresh Suspension Hepatocytes
      • 6.1.1.3. 3D (Spheroid) Hepatocytes
      • 6.1.1.4. Expanded Hepatocytes (Plateable)
      • 6.1.1.5. Non-characterized Hepatocytes
  • 6.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Human
      • 6.2.1.2. Rat
      • 6.2.1.3. Mouse
      • 6.2.1.4. Dog
      • 6.2.1.5. Monkey
      • 6.2.1.6. Horse
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cell Viability Assay
      • 6.3.1.2. Cytochrome Enzyme Activity
      • 6.3.1.3. High Content Cytotoxicity
      • 6.3.1.4. Transporter Inhibition Assay
      • 6.3.1.5. In Vitro Intrinsic Clearance
      • 6.3.1.6. Phospholipids Assay
      • 6.3.1.7. Others
  • 6.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Biopharmaceutical companies
      • 6.4.1.2. Academic and Research institutes
      • 6.4.1.3. Contract Research Organizations
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia & Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.3. China Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.7. Japan Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.11. South Korea Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.15. India Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.19. Southeast Asia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Primary Hepatocytes Market Outlook, 2019-2032

  • 7.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cryopreserved Suspension Hepatocytes
      • 7.1.1.2. Fresh Suspension Hepatocytes
      • 7.1.1.3. 3D (Spheroid) Hepatocytes
      • 7.1.1.4. Expanded Hepatocytes (Plateable)
      • 7.1.1.5. Non-characterized Hepatocytes
  • 7.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Human
      • 7.2.1.2. Rat
      • 7.2.1.3. Mouse
      • 7.2.1.4. Dog
      • 7.2.1.5. Monkey
      • 7.2.1.6. Horse
      • 7.2.1.7. Others
  • 7.3. Latin America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cell Viability Assay
      • 7.3.1.2. Cytochrome Enzyme Activity
      • 7.3.1.3. High Content Cytotoxicity
      • 7.3.1.4. Transporter Inhibition Assay
      • 7.3.1.5. In Vitro Intrinsic Clearance
      • 7.3.1.6. Phospholipids Assay
      • 7.3.1.7. Others
  • 7.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Biopharmaceutical companies
      • 7.4.1.2. Academic and Research institutes
      • 7.4.1.3. Contract Research Organizations
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.3. Brazil Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.7. Mexico Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.9. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.10. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.11. Rest of Latin America Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.12. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Primary Hepatocytes Market Outlook, 2019-2032

  • 8.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cryopreserved Suspension Hepatocytes
      • 8.1.1.2. Fresh Suspension Hepatocytes
      • 8.1.1.3. 3D (Spheroid) Hepatocytes
      • 8.1.1.4. Expanded Hepatocytes (Plateable)
      • 8.1.1.5. Non-characterized Hepatocytes
  • 8.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Human
      • 8.2.1.2. Rat
      • 8.2.1.3. Mouse
      • 8.2.1.4. Dog
      • 8.2.1.5. Monkey
      • 8.2.1.6. Horse
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cell Viability Assay
      • 8.3.1.2. Cytochrome Enzyme Activity
      • 8.3.1.3. High Content Cytotoxicity
      • 8.3.1.4. Transporter Inhibition Assay
      • 8.3.1.5. In Vitro Intrinsic Clearance
      • 8.3.1.6. Phospholipids Assay
      • 8.3.1.7. Others
  • 8.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Biopharmaceutical companies
      • 8.4.1.2. Academic and Research institutes
      • 8.4.1.3. Contract Research Organizations
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Countries Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.2. GCC Countries Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.3. GCC Countries Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.4. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.7. South Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.8. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.9. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.10. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.11. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.12. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.15. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Thermo Fisher Scientific Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Merck KGaA
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. Lonza
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. Takara Bio Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. American Type Culture Collection (ATCC)
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Corning Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. Cell Biologics, Inc.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Creative Bioarray
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Axol Bioscience Ltd.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. HiMedia Laboratories
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development
    • 9.3.11. NEXEL Co., Ltd.
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Product Portfolio
      • 9.3.11.3. Financial Overview
      • 9.3.11.4. Business Strategies and Development
    • 9.3.12. AnaBios
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Product Portfolio
      • 9.3.12.3. Financial Overview
      • 9.3.12.4. Business Strategies and Development
    • 9.3.13. Cytes Biotechnologies S.L.
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Product Portfolio
      • 9.3.13.3. Financial Overview
      • 9.3.13.4. Business Strategies and Development
    • 9.3.14. ZenBio, Inc. (BioIVT)
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Product Portfolio
      • 9.3.14.3. Financial Overview
      • 9.3.14.4. Business Strategies and Development
    • 9.3.15. iXCells Biotechnologies
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Product Portfolio
      • 9.3.15.3. Financial Overview
      • 9.3.15.4. Business Strategies and Development
    • 9.3.16. ScienCell Research Laboratories, Inc.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Product Portfolio
      • 9.3.16.3. Financial Overview
      • 9.3.16.4. Business Strategies and Development
    • 9.3.17. Kerafast
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Product Portfolio
      • 9.3.17.3. Financial Overview
      • 9.3.17.4. Business Strategies and Development
    • 9.3.18. Kosheeka
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Product Portfolio
      • 9.3.18.3. Financial Overview
      • 9.3.18.4. Business Strategies and Development
    • 9.3.19. XenoTech
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Product Portfolio
      • 9.3.19.3. Financial Overview
      • 9.3.19.4. Business Strategies and Development
    • 9.3.20. LifeNet Health LifeSciences
      • 9.3.20.1. Company Overview
      • 9.3.20.2. Product Portfolio
      • 9.3.20.3. Financial Overview
      • 9.3.20.4. Business Strategies and Development
    • 9.3.21. Cell Guidance Systems LLC
      • 9.3.21.1. Company Overview
      • 9.3.21.2. Product Portfolio
      • 9.3.21.3. Financial Overview
      • 9.3.21.4. Business Strategies and Development
    • 9.3.22. Applied Biological Materials Inc. (abm)
      • 9.3.22.1. Company Overview
      • 9.3.22.2. Product Portfolio
      • 9.3.22.3. Financial Overview
      • 9.3.22.4. Business Strategies and Development
    • 9.3.23. Discovery Life Sciences
      • 9.3.23.1. Company Overview
      • 9.3.23.2. Product Portfolio
      • 9.3.23.3. Financial Overview
      • 9.3.23.4. Business Strategies and Development
    • 9.3.24. Innoprot
      • 9.3.24.1. Company Overview
      • 9.3.24.2. Product Portfolio
      • 9.3.24.3. Financial Overview
      • 9.3.24.4. Business Strategies and Development
    • 9.3.25. Novabiosis
      • 9.3.25.1. Company Overview
      • 9.3.25.2. Product Portfolio
      • 9.3.25.3. Financial Overview
      • 9.3.25.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations